Cargando…
A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288668/ http://dx.doi.org/10.1186/2051-1426-2-S3-P55 |
| _version_ | 1782352007327121408 |
|---|---|
| author | Gnanandarajah, Josephine S Ndikuyeze, Georges Habineza Engiles, Julie B Wallecha, Anu Mason, Nicola |
| author_facet | Gnanandarajah, Josephine S Ndikuyeze, Georges Habineza Engiles, Julie B Wallecha, Anu Mason, Nicola |
| author_sort | Gnanandarajah, Josephine S |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288668 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42886682015-01-15 A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial Gnanandarajah, Josephine S Ndikuyeze, Georges Habineza Engiles, Julie B Wallecha, Anu Mason, Nicola J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288668/ http://dx.doi.org/10.1186/2051-1426-2-S3-P55 Text en Copyright © 2014 Gnanandarajah et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Gnanandarajah, Josephine S Ndikuyeze, Georges Habineza Engiles, Julie B Wallecha, Anu Mason, Nicola A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial |
| title | A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial |
| title_full | A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial |
| title_fullStr | A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial |
| title_full_unstemmed | A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial |
| title_short | A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial |
| title_sort | recombinant her2/neu expressing listeria monocytogenes (lm-llo) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a phase i clinical trial |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288668/ http://dx.doi.org/10.1186/2051-1426-2-S3-P55 |
| work_keys_str_mv | AT gnanandarajahjosephines arecombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT ndikuyezegeorgeshabineza arecombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT engilesjulieb arecombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT wallechaanu arecombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT masonnicola arecombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT gnanandarajahjosephines recombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT ndikuyezegeorgeshabineza recombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT engilesjulieb recombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT wallechaanu recombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial AT masonnicola recombinanther2neuexpressinglisteriamonocytogeneslmlloimmunotherapydelaysmetastaticdiseaseandprolongsoverallsurvivalinaspontaneouscaninemodelofosteosarcomaaphaseiclinicaltrial |